|
Vaccine Detail
VHL-59: 116-128 Peptide Vaccine |
Vaccine Information |
- Vaccine Name: VHL-59: 116-128 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007176
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- VHL
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Renal Cancer. A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein (NCIT_C38123).
|
Host Response |
|
References |
NCIT_C38123: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123]
|
|